- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04386395
Immune Changes in Severe COVID-19 Pulmonary Infections (COVIDIMM)
Whole Blood Immune Cells Characterization in Critically Ill COVID-19 Patients: A Prospective Study
SARS-CoV-2 outbreak causes a spectrum of clinical patterns that varies from asymptomatic infection to mildly symptomatic manifestations and more-severe forms that need intensive care. Until now, the immune response to SARS-CoV-2 virus infection has been poorly reported to help decision for immune modulation therapies. As a consequence, trials have been designed to test both anti-inflammatory molecules as steroids or anti-bodies against IL-6, and others proposing to "boost" immunity with interferon beta based on similar inclusion criteria.
The immune response to infective agents including viruses may have a complex time evolution with early and late phases corresponding to different patterns, oscillating between pro-inflammation and immune-depression. The potential window to improve outcome in COVID-19 by therapeutic intervention aimed at a fine tuning between immune toxicity and immunodepression requires a longitudinal assessment during the course of illness, especially for the patients who develop acute respiratory failure. Immune monitoring of both innate and adaptive immunity would then be essential to appropriately design clinical trials.
The whole blood cells evaluation was recorded according to the time intervals between the onset of symptoms and the sampling after ICU admission. Patients' care was standardized, especially with regard to ventilation, sedation, and antimicrobial treatment.
In this study the investigators prospectively perform a longitudinal study of both innate and adaptive immunity on patients admitted to ICU for an COVID-19 related acute respiratory failure. The data will be analyzed in reference to the onset of initial symptoms and also to the admission in ICU.
The primary end point is the evolution of the characterization of monocytes and their subsets in term of number and expression of HLA-DR. A similar approach is used for lymphocytes and their subtypes with in addition, an ex vivo testing of their capabilities to be stimulated by SARS-CoV-2 viral proteins in term of TNFalpha, INFgamma, and IL1beta production.
The secondary end-point was to test the association with outcomes and other non-specific markers of inflammation as CRP (C reactive protein), PCT (procalcitonin), DDimers and ferritin.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The most severe form of COVID-19 treated in intensive care for acute respiratory failure may have a poor prognosis. Both the level of IL-6 and the severity of the lymphopenia have been associated to the poor prognosis. Better knowledge of the time evolution of the circulating immune cells subpopulations and functions will help to best tailor the treatment: anti-inflammatory strategy at the initial phase might be rapidly shifted to immune stimulation when immunodepression is diagnosed.
It is then essential to assess the patients' immune status using flowcytometry methods to characterize both innate and adaptive immunity of the whole blood circulating immune peripheral blood mononuclear cells (PBMC). After cell staining with the adequate cell markers, the flowcytometry (NAVIOS® Flow Cytometer (Beckman Coulter) allowed to analyze the number and the function of the cells with an adequate gating strategy and the Kaluza® software v2.1 (Beckman Coulter). The data were then grouped by time intervals referring to the onset of symptoms and also to the ICU admission. The trend for innate immunity (monocytes number and subpopulations, HLA-DR expression) and for adaptive immunity (lymphocytes and subpopulations) will be analyzed. Since it is unknown if whole blood CD3/CD4 and CD3/CD8 lymphocytes elicit an "exhaustion" pattern and/or an abnormal response, an ex vivo testing of their reactivity for SARS-CoV-2 viral proteins will be performed. This test of polyfunctionality will characterize the intracellular cytokine expression (IL-1 beta, TNFalpha, and INFgamma) both for CD4 and CD8 T cells.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Vandoeuvre-les-Nancy, Francia, 54511
- Centre Hospitalier Universitaire Nancy
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria: confirmed COVID-19
- a positive RT- PCR,
- a highly suggestive thoracic CTScan,
- severe hypoxemia
Exclusion Criteria:
- none
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Immuno Cohort
COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay.
Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
|
Cortico Cohort
COVID-19 confirmed ICU patients, sedated and ventilated, sequential characterization of circulating immune cells over their ICU stay.
According to RECOVERY study, early routine administration of dexamethasone 6 mg/day over 10 days.
Every 2 to 3 days, fresh whole blood aliquots from routine blood counts were processed on a Flow Cytometer (Beckman Coulter) to determine immune cells subpopulations
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Changes in monocytes HLA-DR expression
Periodo de tiempo: through ICU stay, an average of 30 days
|
circulating immune cell characterization
|
through ICU stay, an average of 30 days
|
Changes in lymphocytes subpopulations numbers
Periodo de tiempo: through ICU stay, an average of 30 days
|
circulating immune cell characterization
|
through ICU stay, an average of 30 days
|
Changes in monocytes number
Periodo de tiempo: through ICU stay, an average of 30 days
|
circulating immune cell characterization
|
through ICU stay, an average of 30 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
TNFalpha level
Periodo de tiempo: 4 hours
|
stimulation by SARS-CoV-2 viral proteins
|
4 hours
|
INFgamma level
Periodo de tiempo: 4 hours
|
stimulation by SARS-CoV-2 viral proteins
|
4 hours
|
IL1beta level
Periodo de tiempo: 4 hours
|
stimulation by SARS-CoV-2 viral proteins
|
4 hours
|
SOFA score
Periodo de tiempo: through ICU stay, an average of 30 days
|
Sequential Organ dysfunction assessement, ranging from 0 (better) to 24 (worst) outcome
|
through ICU stay, an average of 30 days
|
number of recorded deaths
Periodo de tiempo: through study completion, an average of 6 months
|
mortality
|
through study completion, an average of 6 months
|
presence of pneumonia
Periodo de tiempo: through ICU stay, an average of 30 days
|
infectious complications
|
through ICU stay, an average of 30 days
|
presence of bacteremia
Periodo de tiempo: through ICU stay, an average of 30 days
|
infectious complications
|
through ICU stay, an average of 30 days
|
presence of urinary tract infection
Periodo de tiempo: through ICU stay, an average of 30 days
|
infectious complications
|
through ICU stay, an average of 30 days
|
C reactive protein
Periodo de tiempo: through ICU stay, an average of 30 days
|
inflammation marker
|
through ICU stay, an average of 30 days
|
D Dimers
Periodo de tiempo: through ICU stay, an average of 30 days
|
inflammation marker
|
through ICU stay, an average of 30 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: MARIE REINE LOSSER, MD, PhD, Central Hospital, Nancy, France
Publicaciones y enlaces útiles
Publicaciones Generales
- Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010 Oct 21;116(16):e74-80. doi: 10.1182/blood-2010-02-258558. Epub 2010 Jul 13.
- Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020 Mar 27;5(1):33. doi: 10.1038/s41392-020-0148-4. No abstract available. Erratum In: Signal Transduct Target Ther. 2020 Apr 29;5(1):61.
- Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013 Dec;13(12):862-74. doi: 10.1038/nri3552. Epub 2013 Nov 15.
- Payen D, Faivre V, Miatello J, Leentjens J, Brumpt C, Tissieres P, Dupuis C, Pickkers P, Lukaszewicz AC. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series. BMC Infect Dis. 2019 Nov 5;19(1):931. doi: 10.1186/s12879-019-4526-x.
- Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020 Oct;92(10):2042-2049. doi: 10.1002/jmv.25964. Epub 2020 May 10.
- Payen D, Cravat M, Maadadi H, Didelot C, Prosic L, Dupuis C, Losser MR, De Carvalho Bittencourt M. A Longitudinal Study of Immune Cells in Severe COVID-19 Patients. Front Immunol. 2020 Oct 23;11:580250. doi: 10.3389/fimmu.2020.580250. eCollection 2020.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CHRU NANCY : 2020PI080_1
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDTerminado
-
Argorna Pharmaceuticals Co., LTDTerminado
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Activo, no reclutando
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Activo, no reclutando
-
Arcturus Therapeutics, Inc.Terminado
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsTerminado
-
Centre Hospitalier Universitaire DijonDesconocido
-
Meshalkin Research Institute of Pathology of CirculationDesconocido
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionAún no reclutando
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological Pharmaceutical...Aún no reclutando